This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

IMCD N.V.
11/5/2026
Hello, welcome to IMCD's 2026 First 9 Months Results Conference Call, hosted by Marcus Jordan, CEO, and Hans Kooijmans, CFO. For the first part of this call, all participants will be in listen-only mode, and afterwards, there will be a question and answer session. If you wish to ask a question, please press pound key 5 on your telephone keypad. I would now like to give the floor to Marcus Jordan. Mr. Jordan, please go ahead.
Thank you, Elba. Good morning to you all, and a warm welcome. I'm Marcus Jordan, and I'm here today with our CFO, Hans Kooijmans, for the 2026 first nine-month results, which we published in a press release earlier this morning. Before we move on to discuss the results, I would like to take this opportunity to note that this is a very special call, as not only is this the last earnings call with Hans, who will retire at the end of this year, but it is also Hans' 50th earnings call. I think we all agree this is quite a remarkable milestone. As announced in December last year, HANZ will be succeeded by Floris Lagererf and I would like to take this opportunity to thank HANZ very much for the smooth transition this year and I'm looking forward to working even more closely together with Floris going forward. Now moving on to the first nine months results, we've had a good year so far with both gross profit and EBITR organic growth and a strong cash conversion. When looking at the overall business, I'm proud of how our teams have navigated through the dynamic environment and focused on the commercial and operational topics which we can control, with the primary aim of getting even closer to our customers and suppliers. It is clear that our partners need us now more than ever, and we need this from a customer perspective in, for example, the amount of formulatory projects we see going through our technical centers or laboratories. and the resulting opportunity pipeline that is developed and converted. Customers also continue to order just in time and it is our job to ensure that we have the right inventory in place to fulfill these requirements. On the supplier side, we continue to focus on delivering what we promise in terms of business simplification, market intelligence, formulatory expertise and growth. As I mentioned on our last call, we also have a healthy pipeline of new supplier projects and some nice wins coming to fruition. Regarding our suppliers, as we also spoke about on the last call, we saw in the second quarter of this year the majority of our suppliers implementing price increases. The magnitude of these price increases varied significantly with the larger specialty part of the portfolio generally receiving much lower percentage increases and showing less volatility than our smaller semi-specialty components. In the third quarter, whilst there was still some price movement, it has generally been much more stable with, I would say, more normal pricing behavior. This more stable message is also applicable from a demand perspective, and we haven't seen any real difference in terms of ordering frequency. When looking across our various markets, our pharmaceutical and food and nutrition segments continue to show resilience and are performing well. In beauty and personal care, we generally see stable to increasing demand versus last year. This is an area that we continue to focus on, as there are good opportunities with the technical capabilities and lab infrastructure we have. This market also has some nice positive trends, like K-beauty in Korea, an area in which we did two acquisitions recently, being YCAM, which we closed last year, and Dunyang FT, which we closed in January this year. On the industrial side, the best way to describe our business in the first nine months is positive, with some bright pockets in areas such as medical plastics, lubricants, and wire and cable for data centers. Moving on to the 2026 first nine months numbers, you will find a summary of our financial results on slide four, where we reported gross profit of 991 million euros, up 9% on a constant currency basis. EBITR was up to €425 million, which is plus 11% on a constant currency basis, and our free cash flow stood at €317 million, leading to a cash conversion margin of 73%, which illustrates our close attention to working capital management and at the same time, as I mentioned earlier, ensuring that we have the right inventory in place to service our customers. In these unpredictable times, it is even more important that we have the highest level of sales activity, that we quickly adapt to changing market conditions, and that we remain a reliable partner for both customers and suppliers. We will continue to focus on the things that we can control and are committed to delivering long-term growth for our partners and stakeholders in the years ahead. Looking forward, it is still early in the fourth quarter, but I can say that we have had a promising start to the quarter. and as you can read in the outlook we have published this morning in our press release, we expect organic operating EBITR growth this year. To summarise and to end my part of the introduction, I believe we have executed well in the first nine months of the year and I see good traction on the commercial, operational and digital excellence initiatives we have been focused on, including continued supplier development and expansion. I would now like to hand over to our CFO, Hans Kooijmans, who will give you an update on the numbers.
Thanks for your kind word, Marcus. Good morning, ladies and gentlemen. And he was right. This is indeed my 50th analyst call. And together with the many other investor meetings and discussions I've had over the years, it has been a real, real pleasure to keep you updated on the developments of IMCD. I'm particularly pleased that the tone of this call, as well as that of our other more recent calls, is considerably more positive than it was about one and a half year ago. And this change in tone is not just a matter of sentiment, as it's clearly reflected in the figures presented on page six of today's analyst call presentation. Taken together, these developments show a clear and also a positive trend underscoring the resilience of IMCD's business model and confirming that we are moving in the right direction to once again have a strong foundation for sustainable organic growth in the years ahead. As you can see on page 6, the Forex adjusted revenue and gross profit both increased with respectively 10 and 9% compared to last year. And this 9% organic gross profit growth, that was a combination of 4% organic and 5% the positive impact of the first time inclusion of acquisitions. These recently acquired companies had on average a slightly lower gross profit margin than those of IMCD. As a consequence, the average gross profit margin of the total group slightly dropped to 25%. But if you would normalize for the impact of these recent acquisitions, the gross profit percentage in 2026 would have been slightly higher than the 25.2% in the first nine months of last year. If you look at the organic growth profit growth development in the first three quarters, you might remember that IMCD reported a minus 4% organic in Q1, then a plus 7% in Q2, and in this quarter, a plus 10% organic growth, and all in all, a positive trend through the year. and this organic growth profit growth combined with the strict cost control resulted in a similar type of outcome for operating EBITDA. At the reported 11% Forex adjusted increase to 425 million was a result of 5% organic and 6% M&A related growth. Organic EBITDA growth in the third quarter was, as Mark had mentioned, 14% but by all segments reported organic EBITDA growth. The year-to-date conversion margin slightly improved with 0.4 percent point to 42.9 and we further report a very healthy free cash flow of 317 million and I will come back on the cash flow in a later slide. The net result and as a consequence also the earnings per share that both increased with 20 percent Forex adjusted. and the increase of cash earnings per share in absolute numbers of 57 cents was slightly higher than the 52 cents earnings per share increase. All in all, solid growth numbers. Compared to September 2025, the number of full-time employees slightly decreased by whereby you should take into account that in the year-to-date 2026 numbers that that includes an additional 150 new employees as a result of the acquisitions that we did in the last 12 months. Then on the next page, slide 7, you will find a summary of a few key figures split into the regional operating segments. You can see a very crowded slide with a lot of numbers, and I could imagine Floris and Tosca will change the format next year. Floris of Tosca is confirming for me that she will do. When looking at the different columns, it's clear that the result of EMEA and APEC are satisfactory. Positive high, single, or even low double-digit organic growth on all lines, combined with high single-digit acquisition growth. As a result of these healthy growth numbers, we were able to improve our EBITDA margin and conversion ratio in both EMEA and APEC. The outcome in the Americas is disappointing. A very weak first quarter of 2026 with a minus 25% organic EBITDA growth, you might remember that number, could not be compensated with the two following quarters whereby we reported modest organic growth profit and modest EBITDA growth. This is definitely a segment which we are working hard on to improve. And in the column holding companies, we report a slightly lower cost base compared to the same period of last year. Then on page 8, a summary of IMCD's free cash flow. The absolute amount of free cash flow was 33 million higher than last year, whereby the cash conversion ratio was 73%. This is, to my opinion, an acceptable number for a third quarter with 6% organic topline growth. Higher operating EBITDA was the main driver of the improvement. Working capital investment was more or less similar as last year, whereby increased stock and debt depositions were the most important drivers of the investment. At the end of the quarter we had a relatively high stock position to cater for the strong Q4 order book. The high adapter positions were the result of strong sales in the quarter. We are confident that we will report at year end a cash conversion ratio somewhere around a high 80 or a low 90% number. Then on page 9, an update on net debt and leverage. Net debt at the end of September was close to 1.5 billion, which is slightly lower than end of December. Reported leverage ratio, including the four-year impact of acquisitions as usual, was 2.6 times EBITDA, which is similar to the leverage based on the definitions in our loan documentation. Then last but not least, on page 10, you will find our outlook for 2026. And as Marcus already mentioned, you could read there that we expect organic operating EBITDA growth in this year. I would like to hand over to Elba, the operator, to open the lines for Q&A.
You're reading a preview of the IMCDY Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing